{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:28:39Z","timestamp":1772011719130,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":2177,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1194\/jlr.r047381","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T05:00:40Z","timestamp":1395810040000},"page":"1996-2003","source":"Crossref","is-referenced-by-count":15,"title":["Development of targeted therapies for Parkinson's disease and related synucleinopathies"],"prefix":"10.1016","volume":"55","author":[{"given":"Edmund","family":"Sybertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Krainc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1194\/jlr.R047381_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the pathogenesis of disease","volume":"132","author":"Levine","year":"2008","journal-title":"Cell."},{"key":"10.1194\/jlr.R047381_bib2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/archneurol.2010.40","article-title":"Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases","volume":"67","author":"Krainc","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1194\/jlr.R047381_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell."},{"key":"10.1194\/jlr.R047381_bib4","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1523\/JNEUROSCI.2978-04.2004","article-title":"Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice","volume":"24","author":"Zu","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1194\/jlr.R047381_bib5","doi-asserted-by":"crossref","first-page":"10076","DOI":"10.1523\/JNEUROSCI.0618-11.2011","article-title":"\u03b1-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies","volume":"31","author":"Lim","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1194\/jlr.R047381_bib6","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/mds.23948","article-title":"Parkinson's disease and \u03b1-synuclein expression","volume":"26","author":"Devine","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1194\/jlr.R047381_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10545-010-9075-9","article-title":"Pathophysiology of neuropathic lysosomal storage disorders","volume":"33","author":"Bellettato","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1194\/jlr.R047381_bib8","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/mds.23774","article-title":"Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond","volume":"26","author":"Shachar","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1194\/jlr.R047381_bib9","first-page":"166","article-title":"Clinical diversity in Gaucher's disease","volume":"146","author":"Sack","year":"1980","journal-title":"Johns Hopkins Med. J."},{"key":"10.1194\/jlr.R047381_bib10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ymgme.2004.11.007","article-title":"Gaucher disease and parkinsonism","volume":"84","author":"Sidransky","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1194\/jlr.R047381_bib11","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","article-title":"Occurrence of Parkinson's syndrome in type I Gaucher disease","volume":"89","author":"Neudorfer","year":"1996","journal-title":"QJM."},{"key":"10.1194\/jlr.R047381_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","article-title":"Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?","volume":"79","author":"Tayebi","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1194\/jlr.R047381_bib13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Goker-Alpan","year":"2004","journal-title":"J. Med. Genet."},{"key":"10.1194\/jlr.R047381_bib14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00401-010-0741-7","article-title":"Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders","volume":"120","author":"Goker-Alpan","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1194\/jlr.R047381_bib15","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","article-title":"Neuropathology provides clues to the pathophysiology of Gaucher disease","volume":"82","author":"Wong","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1194\/jlr.R047381_bib16","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1194\/jlr.R047381_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell."},{"key":"10.1194\/jlr.R047381_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1194\/jlr.R047381_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymgme.2012.11.010","article-title":"Membrane-bound \u03b1-synuclein interacts with glucocerebrosidase and inhibits enzyme activity","volume":"108","author":"Yap","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1194\/jlr.R047381_bib20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid \u03b2-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter \u03b1-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1194\/jlr.R047381_bib21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","article-title":"A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood."},{"key":"10.1194\/jlr.R047381_bib22","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","article-title":"Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study","volume":"116","author":"Lukina","year":"2010","journal-title":"Blood."},{"key":"10.1194\/jlr.R047381_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","article-title":"Eliglustat tartrate: glucosylceramide synthase inhibitor for the treatment of type 1 Gaucher disease","volume":"35","author":"Shayman","year":"2010","journal-title":"Drugs Future."},{"key":"10.1194\/jlr.R047381_bib24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ymgme.2012.01.020","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice","volume":"105","author":"Nietupski","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1194\/jlr.R047381_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type 1 Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1194\/jlr.R047381_bib26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/00498250601094543","article-title":"The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat","volume":"37","author":"Treiber","year":"2007","journal-title":"Xenobiotica."},{"key":"10.1194\/jlr.R047381_bib27","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet."},{"key":"10.1194\/jlr.R047381_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher's disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1194\/jlr.R047381_bib29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1194\/jlr.M021261","article-title":"Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain","volume":"53","author":"Larsen","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R047381_bib30","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s11064-013-0992-5","article-title":"Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice","volume":"38","author":"Arthur","year":"2013","journal-title":"Neurochem. Res."},{"key":"10.1194\/jlr.R047381_bib31","doi-asserted-by":"crossref","first-page":"e43310","DOI":"10.1371\/journal.pone.0043310","article-title":"Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease","volume":"7","author":"Cabrera-Salazar","year":"2012","journal-title":"PLoS ONE."},{"key":"10.1194\/jlr.R047381_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-014-0294-x","article-title":"A GCase chaperone improves motor function in a mouse model of synucleinopathy","author":"Richter","year":"2014","journal-title":"Neurotherapeutics. Epub ahead of print."},{"key":"10.1194\/jlr.R047381_bib33","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting CNS glucocerebrosidase as a therapeutic strategy for Parkinsonism and other Gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.R047381_bib34","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.R047381_bib35","doi-asserted-by":"crossref","first-page":"26052","DOI":"10.1074\/jbc.M113.463562","article-title":"\u03b2-Glucosidase 2 (GBA2) activity and imino sugar pharmacology","volume":"288","author":"Ridley","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R047381_bib36","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/mp200313e","article-title":"Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase","volume":"8","author":"Abian","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1194\/jlr.R047381_bib37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","article-title":"Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations","volume":"35","author":"Alfonso","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1194\/jlr.R047381_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/978-1-4020-8831-5_17","article-title":"Glycosphingolipid disorders of the brain","volume":"49","author":"Boomkamp","year":"2008","journal-title":"Subcell. Biochem."},{"key":"10.1194\/jlr.R047381_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbalip.2004.08.009","article-title":"Lipid and cholesterol trafficking in NPC","volume":"1685","author":"Mukherjee","year":"2004","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1194\/jlr.R047381_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jns.2013.08.033","article-title":"Parkinsonism syndrome in heterozygotes for Niemann-Pick C1","volume":"335","author":"Kluenemann","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1194\/jlr.R047381_bib41","doi-asserted-by":"crossref","first-page":"e6951","DOI":"10.1371\/journal.pone.0006951","article-title":"Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression","volume":"4","author":"Davidson","year":"2009","journal-title":"PLoS ONE."},{"key":"10.1194\/jlr.R047381_bib42","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/NEN.0b013e31825414a6","article-title":"Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C","volume":"71","author":"Stein","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1194\/jlr.R047381_bib43","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1194\/jlr.M040618","article-title":"Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling","volume":"54","author":"Fan","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1194\/jlr.R047381_bib44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s10545-007-0630-y","article-title":"Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year","volume":"30","author":"Chien","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1194\/jlr.R047381_bib45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","article-title":"Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study","volume":"6","author":"Patterson","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1194\/jlr.R047381_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10545-012-9479-9","article-title":"Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C","volume":"36","author":"Chien","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1194\/jlr.R047381_bib47","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/jo061280p","article-title":"Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man","volume":"72","author":"Wennekes","year":"2007","journal-title":"J. Org. Chem."},{"key":"10.1194\/jlr.R047381_bib48","doi-asserted-by":"crossref","first-page":"e21758","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease","volume":"6","author":"Ashe","year":"2011","journal-title":"PLoS ONE."},{"key":"10.1194\/jlr.R047381_bib49","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jmb.2011.03.009","article-title":"Molecular basis for the glycosphingolipid-binding specificity of \u03b1-synuclein: key role of tyrosine 39 in membrane insertion","volume":"408","author":"Fantini","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1194\/jlr.R047381_bib50","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1021\/bi061749a","article-title":"GM1 specifically interacts with alpha-synuclein and inhibits fibrillation","volume":"46","author":"Martinez","year":"2007","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.R047381_bib51","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","article-title":"Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin","volume":"96","author":"Jeyakumar","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.R047381_bib52","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.276.5311.428","article-title":"Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin","volume":"276","author":"Platt","year":"1997","journal-title":"Science."},{"key":"10.1194\/jlr.R047381_bib53","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1098\/rstb.2003.1279","article-title":"Substrate reduction therapy in mouse models of glycosphingolipidosis","volume":"358","author":"Platt","year":"2003","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1194\/jlr.R047381_bib54","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1007\/s10545-009-1261-2","article-title":"Substrate deprivation therapy in juvenile Sandhoff disease","volume":"32(Suppl 1)","author":"Wortmann","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1194\/jlr.R047381_bib55","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1007\/s10545-010-9186-3","article-title":"Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up","volume":"33(Suppl 3)","author":"Masciullo","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1194\/jlr.R047381_bib56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/GIM.0b013e3181a1b5c5","article-title":"Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment","volume":"11","author":"Shapiro","year":"2009","journal-title":"Genet. Med."},{"key":"10.1194\/jlr.R047381_bib57","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/jnr.23090","article-title":"Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans","volume":"90","author":"Wu","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"10.1194\/jlr.R047381_bib58","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jns.2012.10.024","article-title":"A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients","volume":"324","author":"Schneider","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1194\/jlr.R047381_bib59","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2353\/ajpath.2009.080680","article-title":"Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies","volume":"174","author":"Wei","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1194\/jlr.R047381_bib60","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4161\/auto.8825","article-title":"Gangliosides' protection against lysosomal pathology of synucleinopathies","volume":"5","author":"Wei","year":"2009","journal-title":"Autophagy."},{"key":"10.1194\/jlr.R047381_bib61","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1194\/jlr.R047381_bib62","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bcp.2006.12.015","article-title":"Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase","volume":"73","author":"Steet","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1194\/jlr.R047381_bib63","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/cbic.200800249","article-title":"Isofagomine induced stabilization of glucocerebrosidase","volume":"9","author":"Kornhaber","year":"2008","journal-title":"ChemBioChem."},{"key":"10.1194\/jlr.R047381_bib64","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/bi9002265","article-title":"Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability","volume":"48","author":"Lieberman","year":"2009","journal-title":"Biochemistry."},{"key":"10.1194\/jlr.R047381_bib65","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J."},{"key":"10.1194\/jlr.R047381_bib66","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1074\/jbc.M111.280016","article-title":"Ex vivo and in vivo effects of isofagomine on acid \u03b2-glucosidase variants and substrate levels in Gaucher disease","volume":"287","author":"Sun","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R047381_bib67","doi-asserted-by":"crossref","first-page":"e19037","DOI":"10.1371\/journal.pone.0019037","article-title":"Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS ONE."},{"key":"10.1194\/jlr.R047381_bib68","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R047381_bib69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2010.10.012","article-title":"Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant","volume":"46","author":"Bendikov-Bar","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1194\/jlr.R047381_bib70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase","volume":"50","author":"Bendikov-Bar","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1194\/jlr.R047381_bib71","doi-asserted-by":"crossref","first-page":"e69147","DOI":"10.1371\/journal.pone.0069147","article-title":"Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye","volume":"8","author":"Suzuki","year":"2013","journal-title":"PLoS ONE."},{"key":"10.1194\/jlr.R047381_bib72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1194\/jlr.R047381_bib73","doi-asserted-by":"crossref","first-page":"e29861","DOI":"10.1371\/journal.pone.0029861","article-title":"High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase","volume":"7","author":"Goldin","year":"2012","journal-title":"PLoS ONE."},{"key":"10.1194\/jlr.R047381_bib74","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1021\/jm300063b","article-title":"Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase","volume":"55","author":"Patnaik","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1194\/jlr.R047381_bib75","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1074\/jbc.M609304200","article-title":"Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis","volume":"282","author":"Maegawa","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1194\/jlr.R047381_bib76","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ymgme.2010.11.163","article-title":"Pyrimethamine increases \u03b2-hexosaminidase A activity in patients with late onset Tay Sachs","volume":"102","author":"Osher","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1194\/jlr.R047381_bib77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","article-title":"An open-label phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)","volume":"102","author":"Clarke","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1194\/jlr.R047381_bib78","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.chembiol.2006.12.006","article-title":"High-throughput screening for human lysosomal beta-N-acetyl hexosaminidase inhibitors acting as pharmacological chaperones","volume":"14","author":"Tropak","year":"2007","journal-title":"Chem. Biol."},{"key":"10.1194\/jlr.R047381_bib79","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/cmdc.200800350","article-title":"Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease","volume":"4","author":"Rountree","year":"2009","journal-title":"ChemMedChem."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520350033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227520350033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1194\/jlr.R047381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T18:42:41Z","timestamp":1637433761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227520350033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0022227520350033"],"URL":"https:\/\/doi.org\/10.1194\/jlr.r047381","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}